Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.01108

Recent progress of circular RNA in Acute Myeloid Leukemia

  • 1Department of Immunology, School of Basic Medicine, Wuhan University, China
  • 2Department of Immunology, School of Basic Medical Sciences, Wuhan University, China
  • 3Institute of Pathology, Hannover Medical School, Germany
  • 4Department of Hematology, Zhongnan Hospital of Wuhan University, China

Acute myeloid leukemia (AML) is a myeloid malignancy characterized by the proliferation of abnormal and immature myeloid blast in bone marrow. Circular RNA (circRNA) is a novel class of long non-coding RNA with a stable circular conformation regulating various biological processes. The aberrant expression of circRNA and its impact on AML progression has been reported by a number of studies. Despite recent advances in circRNA research, understanding the leukemogenic mechanism of circRNA remains suboptimal. Therefore, translating the current circRNA related research into clinical practices is challenging. This review provides information about functional role and research progress of circRNAs in AML with emphasis on mechanistic insights. The current challenges and opportunities associated with the circRNA related therapeutic research in AML are also outlined.

Keywords: Acute myeloid leukemia, Drug Resistance, Apoptosis, biomarker, Cell Proliferation

Received: 22 Feb 2019; Accepted: 07 Oct 2019.

Copyright: © 2019 Jamal, Song, Chen, Faisal, Hong, Xie, Wu, Pan, Yin, Zhang and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Prof. Qiuping Zhang, Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430072, Hubei Province, China, qpzhang@whu.edu.cn
Dr. Liang Shao, Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China, liangsmd@163.com